Zanubrutinib Better Than Ibrutinib in CLL/SLL?
Zanubrutinib (Brukinsa), a second-generation Bruton tyrosine kinase (BTK) inhibitor, has shown a tremendously elevated extend in disease development vs the regular of care ibrutinib (Imbruvica) in patients with relapsed or refractory power lymphocytic leukemia/exiguous lymphocytic lymphoma (CLL/SLL), with equally encouraging…